The advent of biologic medications has increased considerably the potential for treatment benefit in juvenile idiopathic arthritis (JIA), with clinical remission being now achievable in a substantial proportion of patients. However, there is a need of data from the real world of clinical practice to evaluate thoroughly the efficacy and safety profile of the biologic agents currently approved.
|Numero di pagine||1|
|Rivista||PEDIATRIC RHEUMATOLOGY ONLINE JOURNAL|
|Stato di pubblicazione||Published - 2017|